ALSERepository of Iași University of Life Sciences, ROMANIA

Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity

Show simple item record

dc.contributor.author Vasincu, Alexandru
dc.contributor.author Rusu, Răzvan-Nicolae
dc.contributor.author Ababei, Daniela-Carmen
dc.contributor.author Neamțu, Monica
dc.contributor.author Arcan, Oana-Dana
dc.contributor.author Macadan, Ioana
dc.contributor.author Beșchea Chiriac, Sorin-Ioan
dc.contributor.author Bild, Walther
dc.contributor.author Bild, Veronica
dc.date.accessioned 2024-04-23T11:54:01Z
dc.date.available 2024-04-23T11:54:01Z
dc.date.issued 2023-04-18
dc.identifier.citation Vasincu, Alexandru, Răzvan-Nicolae Rusu, Daniela-Carmen Ababei, Monica Neamțu, Oana Dana Arcan, Ioana Macadan, Sorin Beșchea Chiriac, Walther Bild, and Veronica Bild. 2023. "Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity" Biomedicines 11, no. 6: 1667. https://doi.org/10.3390/biomedicines11061667 en_US
dc.identifier.issn 2227-9039
dc.identifier.uri https://www.mdpi.com/2227-9059/11/6/1667
dc.identifier.uri https://repository.iuls.ro/xmlui/handle/20.500.12811/3806
dc.description.abstract Recently, research has greatly expanded the knowledge of the endocannabinoid system (ECS) and its involvement in several therapeutic applications. Cannabinoid receptors (CBRs) are present in nearly every mammalian tissue, performing a vital role in different physiological processes (neuronal development, immune modulation, energy homeostasis). The ECS has an essential role in metabolic control and lipid signaling, making it a potential target for managing conditions such as obesity and diabetes. Its malfunction is closely linked to these pathological conditions. Additionally, the immunomodulatory function of the ECS presents a promising avenue for developing new treatments for various types of acute and chronic inflammatory conditions. Preclinical investigations using peripherally restricted CBR antagonists that do not cross the BBB have shown promise for the treatment of obesity and metabolic diseases, highlighting the importance of continuing efforts to discover novel molecules with superior safety profiles. The purpose of this review is to examine the roles of CB1R and CB2Rs, as well as their antagonists, in relation to the above-mentioned disorders. en_US
dc.language.iso en en_US
dc.publisher MDPI en_US
dc.rights
dc.rights.uri
dc.subject drug addiction en_US
dc.subject immunomodulation en_US
dc.subject inflammation en_US
dc.subject obesity en_US
dc.subject diabetes en_US
dc.subject endocannabinoid system en_US
dc.title Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity en_US
dc.type Article en_US
dc.author.affiliation
dc.author.affiliation
dc.publicationName
dc.volume
dc.issue
dc.publicationDate
dc.identifier.doi https://doi.org/10.3390/biomedicines11061667


Files in this item

This item appears in the following Collection(s)

Show simple item record